Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $25.1875.

ROIV has been the subject of several research reports. Wall Street Zen raised Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Jefferies Financial Group lifted their target price on shares of Roivant Sciences from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, September 18th. Weiss Ratings raised shares of Roivant Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Saturday, October 25th. Leerink Partners raised their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a research note on Monday, December 15th. Finally, Bank of America lifted their price objective on Roivant Sciences from $12.00 to $16.50 and gave the company a “neutral” rating in a report on Thursday, September 18th.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, Director Daniel Allen Gold sold 777,332 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $23.07, for a total transaction of $17,933,049.24. Following the completion of the transaction, the director directly owned 16,353,113 shares in the company, valued at $377,266,316.91. This represents a 4.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Richard Pulik sold 406,731 shares of Roivant Sciences stock in a transaction on Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total value of $9,122,976.33. Following the transaction, the chief financial officer directly owned 239,413 shares of the company’s stock, valued at approximately $5,370,033.59. The trade was a 62.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 12,983,775 shares of company stock valued at $276,477,147. 10.80% of the stock is owned by insiders.

Institutional Trading of Roivant Sciences

Several large investors have recently added to or reduced their stakes in the company. Amundi raised its stake in shares of Roivant Sciences by 18.1% in the first quarter. Amundi now owns 398,729 shares of the company’s stock valued at $3,991,000 after acquiring an additional 61,214 shares during the last quarter. Teza Capital Management LLC bought a new position in Roivant Sciences in the 1st quarter valued at $205,000. Goldman Sachs Group Inc. boosted its stake in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock worth $24,553,000 after purchasing an additional 324,764 shares in the last quarter. Clearline Capital LP acquired a new position in Roivant Sciences in the first quarter worth $1,211,000. Finally, Zimmer Partners LP grew its holdings in shares of Roivant Sciences by 111.3% during the first quarter. Zimmer Partners LP now owns 534,500 shares of the company’s stock worth $5,393,000 after purchasing an additional 281,600 shares during the last quarter. 64.76% of the stock is owned by institutional investors.

Roivant Sciences Trading Up 0.9%

Shares of ROIV stock opened at $21.98 on Monday. The stock has a 50 day moving average of $21.21 and a two-hundred day moving average of $16.25. Roivant Sciences has a 12 month low of $8.73 and a 12 month high of $23.47. The company has a market capitalization of $15.29 billion, a P/E ratio of -39.25 and a beta of 1.22.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.